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Felix Liebau1, Martin Sundström1, Luc JC van Loon2, Jan Wernerman1 and Olav Rooyackers1*Abstract
Introduction: Evidence behind the recommendations for protein feeding during critical illness is weak. Mechanistic
studies are needed to elucidate the effects of amino acid and/or protein supplementation on protein metabolism
before larger clinical trials with higher levels of protein feeding are initiated.
Methods: We studied the effects of parenteral amino acid supplementation (equivalent to 1 g/kg/day) over the
course of 3 hours on whole-body protein turnover in critically ill patients in the intensive care unit (ICU) during the
first week after admission. Patients were studied at baseline during ongoing nutrition and during extra amino acid
supplementation. If the patient was still in the ICU 2 to 4 days later, these measurements were repeated. Protein
kinetics were measured using continuous stable isotope-labeled phenylalanine and tyrosine infusions.
Results: Thirteen patients were studied on the first study occasion only, and seven were studied twice. Parenteral amino
acid supplementation significantly improved protein balance on both occasions, from a median of −4 to +7 μmol
phenylalanine/kg/hr (P =0.001) on the first study day and from a median of 0 to +12 μmol phenylalanine/kg/hr (P =0.018)
on the second study day. The more positive protein balance was attributed to an increased protein synthesis rate, which
reached statistical significance during the first measurement (from 58 to 65 μmol phenylalanine/kg/hr; n =13; P =0.007),
but not during the second measurement (from 58 to 69 μmol phenylalanine/kg/hr; n =7; P =0.09). Amino acid oxidation
rates, estimated by phenylalanine hydroxylation, did not increase during the 3-hour amino acid infusion. A positive
correlation (r =0.80; P <0.0001) was observed between total amino acids and/or protein given to the patient and
whole-body protein balance.
Conclusion: Extra parenteral amino acids infused over a 3-hour period improved whole-body protein balance and did
not increase amino acid oxidation rates in critically ill patients during the early phase (first week) of critical illness.Introduction
Critically ill patients are characterized by a progressive
loss of lean body mass, mainly confined to skeletal
muscle mass. The loss of this lean body mass is related
to a worsened outcome. The most obvious way to prevent
this is by adequate nutrition, including protein feeding.
Although the effects of varying caloric and protein supply
have been addressed in clinical studies, the evidence
underlying clinical recommendations for protein feeding
in critically ill patients remains weak, as reviewed by
Hoffer and Bistrian [1]. Current recommendations for
protein intake in critically ill patients vary between 1.2 and* Correspondence: olav.rooyackers@ki.se
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unless otherwise stated.2.5 g/kg/day [1-3], also indicating the uncertainty of the
scientific evidence for the recommendations. Smaller
physiological, and subsequently larger, clinical trials are
needed to solve this problem.
Protein requirements are mostly studied by measuring
nitrogen balance in response to a certain diet. However,
the validity of the nitrogen balance technique to assess
the effects of different protein feeding regimens over a
short period (less than a few weeks) has been questioned
[4]. We have previously applied stable isotope amino
acid tracer techniques to study the impact of varying
feeding strategies on whole-body protein metabolism in
critically ill patients. This methodology allows for a direct
measurement of the impact of a feeding regimen on in vivo
protein breakdown, protein synthesis, protein balance and
amino acid oxidation. We found that patients with head
trauma had a better protein balance when fed standardThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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iture (indirect calorimetry) than when fed 50% [5]. However,
it remains unclear whether this effect is due to increases in
the caloric supply, the amino acid supply, or both.
In the present study, we investigated the effect of an
increased parenteral amino acid supply on top of
ongoing nutrition in critically ill patients during the first
week of intensive care unit (ICU) treatment. The first
week was chosen because the largest deficit in cumulative
nutritional supply is normally established in this patient
group [6]. To achieve this, we first performed a pilot study
to validate the use of a free stable isotope-labeled
phenylalanine tracer to measure the splanchnic protein
extraction during ongoing feeding. In the actual study, we
then addressed three questions. The primary question was
whether extra parenteral amino acids during the first week
in the ICU modulate whole-body protein balance. The
two secondary questions were whether baseline protein
balance changes during early ICU treatment and whether
the effects of extra parenteral amino acids are maintained
after a few days.
Materials and methods
Pilot study
To measure whole-body protein turnover during ongoing
enteral nutrition, two distinct tracers of the same amino
acid need to be given, one parenterally and one enterally.
This is necessary to correct the appearance of the enteral
amino acids for the splanchnic extraction (that is, the
fraction of dietary amino acid that is not available
systemically). Because the digestion and absorption
kinetics of protein may be different from those of free
amino acids given enterally, the enteral tracer should
preferentially be given within the matrix of the food
provided [7,8]. Previous work has successfully produced
intrinsically [1-13C]phenylalanine-labeled milk proteins by
infusing Holstein cows with large amounts of tracer [7].
Although the kinetics of dietary intact protein versus freeTable 1 Patient characteristics
Pilot study
(n =6)
Q1 effect AA
(n =13)
Q2 time
(n =10, s
First study day First stud
Age, yr 70 (61 to 79) 69 (46 to 77) 71 (46 to
Sex, male/female 3/3 8/5 6/4
Weight, kg 75 (63 to 95) 85 (42 to 146) 92 (70 to
Diagnosis, medical/surgical 2/4 7/6 4/6
SAPS III 73 (41 to 76) 70 (54 to 93) 70 (54 to
Days in ICU 4 (3 to 48) 5 (3 to 7) 4 (3 to 6)
SOFA score on study day 8 (1 to 12) 7 (2 to 14) 6 (2 to 14
Characteristics for the patients included in the pilot study and the different cohorts
parenteral amino acids (AA) during the first week in the intensive care unit (ICU) m
during early ICU treatment? Q3: Are the effects of extra parenteral amino acids mai
cohort (P <0.05 by Wilcoxon signed-rank test). SAPS III, Simplified Acute Physiologyamino acids have been investigated using bolus feeding in
healthy persons, the situation in critically ill patients may
differ substantially because of the use of continuous feeding,
physiological changes affecting gastric emptying, protein
digestion and amino absorption, and the use of drugs
such as opioids and proton pump inhibitors. We
therefore first investigated whether the enteral tracer
kinetics from an intrinsically labeled protein and a
free amino acid might behave similarly after a few hours of
continuous enteral feeding via a feeding tube. To test this
hypothesis, we performed a pilot study in which six critic-
ally ill patients treated in the ICU received an enteral feed
containing both intrinsically [1-13C]-phenylalanine-labeled
casein [7] (isotopic enrichment 35.2% molar percent excess
(MPE)) and a free [ring-2H5]phenylalanine tracer together
with maltodextrin for 6 hours. None of the six patients had
received any previous enteral nutrition while in the ICU.
The enteral feed was given as 1.5 g/hr labeled casein
(resulting in 0.068 g/hr phenylalanine), 2.7 g/hr
maltodextrin and 0.068 g/hr free 2H5-phenylalanine.
Plasma samples were taken from an existing arterial
line and analyzed for both [13C]phenylalanine and
[2H5]phenylalanine as described previously [9]. The rate of
appearance estimated by the two enterally given tracers
was calculated by dividing the infusion rate of each tracer
given enterally by the plasma enrichment (in atom percent
excess) per kilogram of body weight.
The patients’ characteristics are shown in Table 1. For
one patient, neither of the two tracers was detected in
arterial plasma. For the other five, the initial appearance
was very different for the two tracers, with the free
amino acid tracer appearing much faster. However, after
4 hours, the appearance rates were similar for the
remaining 2 hours (see Figure 1 for mean values and
Additional file 1 for individual curves). On the basis of
these results, we conclude that whole-body protein
kinetics measurements during ongoing continuous enteral
nutrition in critically ill patients can be assessed by addingeffect basal
ubgroup of Q1)
Q3 time effect AA
(n =7, subgroup of Q2)
y day Second study day First study day Second study day
77) 71 (46 to 77)
4/3
146) 81 (70 to 138)
3/4
93) 73 (54 to 93)
7 (5 to 10)* 4 (3 to 6) 7 (5 to 10)*
) 7 (2 to 15) 7 (3 to 14) 5 (2 to 15)
to evaluate the three research questions (Q1 through Q3). Q1: Do extra
odulate whole-body protein kinetics? Q2: Do baseline protein kinetics change
ntained after a few days? *Significantly different from first study day in same
Score III; SOFA, Sequential Organ Failure Assessment.
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Figure 1 Plasma enrichments (A) and rate of appearance (B) measured with 13C-phenylalanine intrinsically labeled casein protein
(35.2 molar percent excess (MPE)) and with the same amount of free [2H5]phenylalanine (99.7 MPE) given enterally together with
maltodextrin in six critically ill patients for 6 hours. The rate of appearance is an apparent rate of appearance of phenylalanine (not corrected
for splanchnic extraction) into the central circulation and is calculated by dividing the enteral infusion rate of the two tracers by the plasma
enrichment of each tracer at each time point. In one patient, none of the tracers escaped the splanchnic tissues, so mean values and standard
deviations of five patients are shown. After about 4 hours, the rate of appearance was identical for both tracers. The individual data for these
patients are given in Additional file 1.
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and measuring after a 4-hour run-in period. This result
also shows that the digestion capacity for casein is not
compromised in these critically ill patients.
Parenteral amino acids study
In this study, we addressed three questions. The primary
question was whether extra amino acids given as 3-hour
parenteral supplementation can be used in critically ill
patients to improve protein turnover and balance during
the initial week after ICU admission. The two secondary
questions were (1) whether basal protein turnover rates
are stable during the initial phase of ICU stay and (2)
whether the response to extra parenteral amino acids is
maintained. We therefore recruited patients admitted to
the general ICU at Karolinska University Hospital in
Huddinge, Sweden, during the initial week after admission
and studied them during ongoing parenteral and/or enteral
nutrition. Patients were studied again if still present in theICU 2 to 4 days later. Both this study and the pilot study
were approved (2011/2019-31/1) by the regional ethical re-
view board in Stockholm (etikprövningsnämnden). Patients
and relatives were informed about the study orally and in
writing before written informed consent was obtained.
Study protocol
The study was designed as a pragmatic intervention
study, meaning that standard care, including nutritional
support, was continued. Nutrition routines included
early initiation of enteral nutrition and supplementary
parenteral nutrition if needed after day 5 in the unit.
Energy targets were set according to energy expend-
iture measured by indirect calorimetry or otherwise at
20 kcal/kg/day. Protein targets were set at 1.2 g/kg/day.
Glutamine supplementation was given only to patients
receiving parenteral nutrition who had low plasma
glutamine concentrations (<500 μM). Nutrition was not
changed during ongoing measurements for the study,
15 patients included
14 patients studied in first
 ICU week 
13 patients studied in first
week with amino acid
supplementation
10 patients studied2 nd
time 
7 patients studied 2
nd
time with amino acid 
supplementation
Protocol violation in 1 patient
1 patient lost arterial accessduring study
1 patient lost due to change in enteral nutrition under study,
2 patients were discharged from the ICU after 1
st
 study period
1 patient lost due to extubation during study period,
1 patient lost due to transfer to other ICU,
1 patient was discharged from the ICU
Q1: effect of amino acid supplementation 
Q3: change in response to extra amino acids over time
Q2: change in basal protein turnover over time
Figure 2 CONSORT diagram of the number of patients included into the study. Because of the pragmatic nature of the study, the cohorts
of patients studied to answer the three research questions were not identical. ICU, Intensive care unit.
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stopped at least 8 hours before the start of the study.
Whole-body protein kinetics were measured during
the initial week of the ICU stay, first during the baseline
situation and again following 3 hours of parenteral amino
acid supplementation at an equivalent of 1 g/kg/day. A
second, identical study was performed 2 to 4 days later if
the patient was still in the ICU. Patients with ongoing
hemodialysis, without arterial access for sampling, or
younger than 18 years of age were excluded from
participating in the study.
On the study day at time 0, ongoing enteral nutrition
was supplemented with [1-13C]-phenylalanine to obtain a
30% enrichment (MPE) in the total phenylalanine content
in the enteral nutrition. Two hours later (time (t) =2 hours)
a primed continuous intravenous infusion of [ring-2H5]
phenylalanine, [2H4-]tyrosine and [
2H2]tyrosine was
started. The prime consisted of 0.5 mg/kg [ring-2H5]
phenylalanine, 0.15 mg/kg [ring-2H4]tyrosine and
0.3 mg/kg [3,3-2H2]tyrosine and was immediately
followed by a continuous infusion of 0.5 mg/kg/hr
[ring-2H5]phenylalanine and 0.3 mg/kg/hr [3,3-
2H2]
tyrosine. After another 3 hours (t =5 hours), an infusion
with a mixture of amino acids (Glavamin; Fresenius Kabi,
Uppsala, Sweden) was started in a central venous catheter
at a rate of 0.083 g/kg/hr total amino acids (equivalent to
1 g/kg/day) and maintained for 3 hours (until t =8 hours).Ethylenediaminetetraacetic acid plasma samples were
obtained just before time 0 and during the last half-hour
of the baseline (t = 4.5 to 5 hours) and of the intervention
period (t =7.5 to 8 hours). During each of the latter two
periods, four samples were obtained at 10-minute
intervals. Plasma samples were kept at −80°C until
analysis by gas chromatography–mass spectrometry as
described previously [9]. In addition, the last samples of
the baseline and intervention periods were analyzed for
amino acid concentrations [10] and urea (kit for Konelab;
Thermo Scientific, Stockholm, Sweden). The calculated
sum of total amino acids includes the amino acids given
by the supplementation minus proline, which is not
analyzed in our method.
Calculations and statistics
Whole-body protein kinetics, including protein breakdown
(endogenous rate of appearance), phenylalanine oxidation
(estimated by phenylalanine hydroxylation rate), protein
synthesis (rate of disappearance minus phenylalanine
hydroxylation rate), splanchnic extraction and protein bal-
ance (difference between breakdown and synthesis rates)
were calculated using formulas published elsewhere [9,11].
Mean enrichments of the four plasma samples from each
sampling period were used for these calculations.
All data are presented as median (range). The three
questions addressed were statistically analyzed separately.
Table 2 Nutrition
Total energy
intake
Total protein
intake
(kcal/kg/day) (g/kg/day)
Q1 effect AA (n =13)
First basal 17 (0 to 26) 0.7 (0.0 to 1.0)
First AA 21 (4 to 30) 1.6 (1.0 to 2.0)
P-value 0.001 0.001
Q2 time effect basal (n =10)
First basal 16 (0 to 21) 0.6 (0.0 to 1.0)
Second basal 18 (0 to 36) 0.7 (0.0 to 1.4)
P-value 0.09 0.11
Change from first to second 8 (−21 to 23) 0.3 (−1.0 to 0.9)
Q3 time effect AA (n =7)
First basal 14 (0 to 20) 0.5 (0.0 to 0.8)
First AA 17 (4 to 24) 1.5 (1.0 to 1.7)
P-value 0.017 0.017
Second basal 20 (10 to 36) 0.8 (0.4 to 1.4)
Second AA 24 (14 to 40) 1.7 (1.4 to 2.3)
P-value 0.017 0.017
The data reflect the amount of energy and protein given to the three different
patients cohorts during the basal and amino acid supplementation (AA)
measurements to answer the three research question (Q1 to Q3). Question 1:
Do extra parenteral amino acids during the first week in the intensive care
unit (ICU) modulate whole body protein kinetics? Question 2: Do baseline
protein kinetics change during early ICU treatment? Question 3: Are the effects
of extra parenteral amino acids maintained after a few days? P-values indicate
statistically significant difference from basal (Wilcoxon signed-rank test).
Liebau et al. Critical Care  (2015) 19:106 Page 5 of 10Nonparametric analyses were performed with Mann–
Whitney, Wilcoxon and Friedman tests, as appropriate,
using Statistica 10 software (StatSoft, Uppsala, Sweden).
Results
Fifteen critically ill patients were included in the study
(Figure 2). Data from 13 patients were used to address
the primary question. Of these, ten patients were studied
again at baseline to address the second question. Ultimately,
seven patients were studied twice, both at baseline and
during amino acid supplementation, to address the third
question. The characteristics of the patients in the three
cohorts are given in Table 1. The three cohorts were com-
parable with regard to age, sex, weight, diagnosis, Simplified
Acute Physiology Score III and Sequential Organ Failure
Assessment score. Of the patients included to address
question 1, 12 of 13 received insulin and 5 of 13 received
noradrenaline during the measurements. Of the patients
included to address question 2, ten of ten received insulin
on first day and nine of ten on the second day, and five of
ten received noradrenaline during the first day and three of
ten on second day. Of the patients included to address
question 3, seven of seven received insulin during the first
day and seven of seven the second day, and five of seven
received noradrenaline on day 1 and two of seven on day 2.
The amounts of energy and protein given are shown in
Table 2. Because nutrition was given according to clinical
routines at the discretion of the attending intensivist, a
large variation in the amount of energy and protein given
to the patients was observed. Energy and protein intake
increased during the intervention period, owing to the
amino acid supplementation. However, both energy and
protein intake during the baseline periods on the 2 study
days were similar.
Most amino acids given during amino acid supplemen-
tation increased in plasma concentration after 3 hours
(see Additional file 2). The sum of total amino acid
concentration increased from 2.0 (1.2 to 3.2) mM to
2.6 (1.7 to 4.0) mM on study day 1 (P =0.001) and
from 2.0 (1.5 to 2.7) mM to 2.3 (1.9 to 4.0) mM on
study day 2 (P =0.01) (Figure 3).
The results of the protein turnover measurements for
the three cohorts are summarized in Table 3. The results
for protein synthesis, protein breakdown, protein balance
and oxidation (estimated by phenylalanine hydroxylation)
for questions 1 and 3 are shown in Figure 4. For the
13 patients assessed on study day 1, protein synthesis
and protein balance increased during amino acid sup-
plementation, whereas no changes in protein breakdown
or oxidation rates were observed. Splanchnic extraction
decreased. For the ten patients studied again at baseline, 2
to 4 days later no changes were observed as compared
with the initial baseline measurements. For the seven
patients studied at baseline and during amino acidsupplementation on both study days, no significant
differences in the response to the amino acid supplementa-
tion were observed (Table 3). The protein balance increased
on both days with amino acid supplementation (Figure 4).
The protein synthesis rate increased, which reached
statistical significance during the first measurement (from
58 to 65 μmol/kg/hr phenylalanine) (n =13; P =0.007),
but not during the second measurement (from 58 to
69 μmol/kg/hr phenylalanine) (n =7; P =0.09). Protein
oxidation rates, estimated based on the phenylalanine
hydroxylation rate, were not changed on both days
during the amino acid supplementation.
Plasma urea levels did not change from baseline during
amino acid supplementation (Figure 5).
When the actual amino acid and/or protein intake for
all the patients at all time points was compared with
the protein balance, a positive correlation was observed
(r =0.80; P <0.0001) (Figure 6). No correlation with
protein oxidation rates was observed (r =0.02; P =0.88)
(Figure 6). For these comparisons, the protein balance and
protein oxidation rates are presented in grams of protein
per kilogram of body weight per day. The calculations
were performed assuming that the phenylalanine content
of the human whole-body protein pool was 4% [12].
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Figure 3 Sum of all amino acids in plasma of critically ill patients during baseline and parenteral amino acid supplementation (AA) on
2 study days. On the first study day, 13 patients were studied, and on the second study day, 7 of these patients were still being treated in the
intensive care unit and were studied again. The seven patients studied twice are indicated by continuous lines, and the other five studied on day
1 only are indicated by dashed lines. Individual values are shown, with the median in red. The sum of amino acids consists of glutamate, serine,
glutamine, histidine, glycine, threonine, arginine, alanine, tyrosine, valine, methionine, tryptophan, phenylalanine, isoleucine, leucine and lysine.
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The main result of the present study is that, during the
first week of ICU treatment, extra amino acids could be
used in critically ill patients during a short period of
parenteral supplementation to improve whole-body proteinTable 3 Whole-body protein kinetics
Breakdown Synthesis
Q1 effect AA (n =13)
First basal 60 (32 to 99) 58 (34 to
First AA 62 (25 to 82) 65 (40 to
P-value 0.92 0.007
Q2 time effect basal (n =10)
First basal 59 (32 to 99) 54 (34 to
Second basal 60 (35 to 95) 59 (29 to
P-value 0.17 0.45
Q3 time effect AA (n =7)
Change from first basal to AA 3 (−24 to 12) 12 (−13 to
Change from second basal to AA −1 (−22 to 6) 4 (−11 to
P-value 0.40 0.50
The data represent whole-body protein turnover rates of the three patient cohorts
phenylalanine per kilogram of body weight per hour, except for the splanchnic extr
acids (AA) during the first week in the intensive care unit (ICU) modulate whole-bod
early ICU treatment? Question 3: Are the effects of extra parenteral amino acids ma
question 1 between amino acid supplementation (AA) and basal; for question 2, be
the change from basal to supplementation on study days 1 and 2, respectively (Wilbalance. When this intervention was repeated 2 to 4 days
later, the response was similar. Whole-body protein
turnover did not appear to change during the initial
week following ICU admission. The improvement in
protein balance due to the extra parenteral amino acidsBalance Splanchnic extraction Oxidation
90) −4 (−21 to 5) 0.4 (0.2 to 0.6) 11 (5 to 24)
87) 7 (−10 to 14) 0.2 (−0.1 to 0.9) 11 (4 to 21)
0.001 0.037 0.47
90) −5 (−21 to 5) 0.4 (0.2 to 0.6) 9 (5 to 21)
95) −5 (−18 to 5) 0.3 (−0.1 to 0.9) 11 (5 to 26)
0.80 0.31 0.20
21) 10 (9 to 16) −0.1 (−0.4 to 0.2) 0 (−2 to 6)
25) 12 (4 to 25) 0 (−0.1 to 0.5) −1 (−16 to 3)
0.50 0.14 0.40
to answer the three research questions (Q1 to Q3), expressed as micromolar
action, which is shown as a fraction. Question 1: Do extra parenteral amino
y protein kinetics? Question 2: Do baseline protein kinetics change during
intained after a few days. P-values indicate statistically significant difference for
tween basal measurements on the 2 study days; and for question 3, between
coxon signed-rank test).
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Figure 4 Whole-body protein breakdown (A), protein synthesis (B), protein balance (C) and phenylalanine oxidation (D) in critically ill
patients during baseline and parenteral amino acid supplementation (AA) on 2 study days. On the first study day, 13 patients were
studied, and on the second study day, 7 of these patients were still being treated in the intensive care unit and were studied again. The seven
patients studied twice are indicated by continuous lines, and the other five studied on day 1 only are indicated by dashed lines. Individual values
are shown, with the median in red.
Liebau et al. Critical Care  (2015) 19:106 Page 7 of 10was attributable mainly to an increased protein synthesis
rate, which attained statistical significance during first
study day, but not during the second study day, on which
fewer patients were included. In addition, no increase in
phenylalanine hydroxylation rate was observed during
amino acid supplementation. These results, together with
the unchanged plasma urea levels, imply that none of the
supplemental amino acids given were oxidized. In a pilot
study, we also show that the enteral protein kinetics could
be assessed with the addition of a free amino acid tracer to
the enteral nutrition, as long as the patients were fed con-
tinuously and a 4-hour run-in period was taken into ac-
count. We also show, in the pilot study, that enterally
given free labeled phenylalanine, instead of an intrin-
sically labeled protein, could be used in continuously
fed critically ill patients to estimate splanchnic extraction
for whole-body protein kinetics. This result from thepilot study also shows that these critically ill patients
were able to fully digest the protein given to them, in this
case casein.
It is well known that many critically ill patients are
severely catabolic and lose mainly muscle protein. The
most obvious way to prevent or counteract this loss is
by protein feeding. However, the recommendations for
the amount of protein to be given are based on weak
evidence [1]. In addition, the preferred route of adminis-
tration (parenteral or enteral) remains uncertain. There
is also evidence that overfeeding, or even any feeding,
during the initial week of an ICU stay might extend ICU
stay [13]. It is well established that parenteral amino acid
supplementation increases protein balance in healthy
humans, with most studies showing that this is attributable
to both an increase in protein synthesis rate and a decrease
in breakdown rate [14]. Our results suggest that the effect
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Figure 5 Plasma urea concentrations in critically ill patients
during baseline and parenteral amino acid supplementation
(AA) on 2 study days. On the first study day, 13 patients were
studied, and on the second study day, 7 of these patients were still
being treated in the intensive care unit and were studied again. The
seven patients studied twice are indicated by continuous lines, and
the other five studied on day 1 only are indicated by dashed lines.
Individual values are given, with the median in red.
Liebau et al. Critical Care  (2015) 19:106 Page 8 of 10in critically ill patients is attributable mainly to increases in
protein synthesis rates. However, these increases could also
be a result of the choice of the labeled amino acid because
different amino acids tracers can show a similar response
on protein balance, but by different mechanisms [9].
Nonetheless, previous work in healthy humans using
the same amount of amino acid supplementation as
we used in the present study also showed an increase
in protein synthesis rates only [15]. Our patients, how-
ever, were older than most of the healthy volunteers in
these previous studies. However, also in older adults
(mean age, 73±3 years), a parenteral amino acid infusion
is able to increase whole-body protein balance to the
same extend as in younger healthy volunteers [16]. How-
ever, for enteral supplementation, this might be different
because of increased splanchnic extraction in the older
adults [17].
Most studies in which researchers have investigated
the effects of parenteral amino acids in critically ill
patients and healthy volunteers have been focused on
the effect over a few hours only. In the present study,
the anabolic effect was observed after 3 hours, but
whether these effects are sustained over more prolonged
periods was not studied. In preterm infants, an anabolic
effect of short amino acid supplementation was observed,
but it did not persist after 24 hours [18]. However, in
a recent study on the effect of high (2.8 g/kg/day)
parenteral amino acid supplementation versus a normal
dose (1.5 g/kg/day) in critically ill adolescents, researchers
showed that, even after 24 hours of supplementation, amore positive whole-body protein balance could be
achieved with the higher dose [19]. However, both
these studies included critically ill patients of much
younger age than the patient cohort in our present
study.
The present study was designed as a pragmatic study,
implying that no interference with treatment, including
nutritional support, was made. The only intervention was
that intravenous glutamine supplementation was stopped
several hours before the study because the amino acid
supplementation we used also contained glutamine. This
pragmatic approach was associated with dropout of
patients during the ongoing study and a large variation in
the amount of nutrition given. A rather wide range—
between 0 and 1.4 g/kg/day—of protein and/or amino acid
supply was already observed at the baseline measurements.
With the additional parenteral amino acid supplementa-
tion, the range for all the measurements increased to
between 0 and 2.3 g/kg/day equivalent. When the amount
of the actual ongoing protein and/or amino acid feeding
was correlated to whole-body protein balance, a positive
correlation (r =0.80; P <0.0001) was observed (Figure 6).
No significant correlation was observed between
amino acid and/or protein feeding and phenylalanine
hydroxylation rates representing protein oxidation
rates (Figure 6). These results imply that, during the
initial 10 days following ICU admission, additional
proteins and/or amino acids could be used in critically ill
patients for building protein, irrespective of background
nutritional support, and that the supplemental amino
acids provided were not oxidized.
The increases in whole-body protein balance and protein
synthesis by the extra parenteral amino acid administration
in the present study do not reveal where these effects are
located. On the basis of the whole-body measurements, it is
not clear which proteins were synthesized or in which
tissues. In healthy humans, extra parenteral amino acids
have been shown to increase muscle protein synthesis
[14,15], which also is the preferred target in critically ill
patients if the goal is to preserve muscle mass and function.
However, several studies have shown that the loss of muscle
protein in the critically ill is mainly the result of an
increased protein breakdown rate and not of a decreased
synthesis rate [20-22]. Thus, the extra parenteral amino
acids may also be used to synthesize other proteins in
different tissues. Specific studies measuring protein
turnover of specific proteins or tissues are necessary
to elucidate this.
The strengths of our study are that we used a prag-
matic approach with minimal alterations in standard
care, making the results applicable to real-life settings,
and that we used a balanced amino acid supplement that
included all amino acids. Many commercial parenteral
amino acid solutions lack both glutamine and tyrosine
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Figure 6 Statistical correlations between total amino acid and/or protein feeding and whole protein balance (A) and protein oxidation
rate (B) in 13 critically ill patients during baseline and parenteral amino acid supplementation (AA) on 2 study days. On the first study
day, 13 patients were studied, and on the second study day, 7 of these patients were still being treated in the intensive care unit and were
studied again. All measurements performed for all patients are included. The protein balance is presented in grams of protein per kilogram of
body weight per day. This was calculated assuming that the phenylalanine content of the human whole-body protein pool is 4% [12]. A positive
correlation with r =0.80 (P <0.0001) was observed between the amino acid and/or protein feeding and whole-body protein balance. No correlation
with phenylalanine oxidation was observed (r =0.02; P =0.88).
Liebau et al. Critical Care  (2015) 19:106 Page 9 of 10because of instability and low solubility. The solution we
used contains both these amino acids in the form of
dipeptides (glycyl-glutamine and glycyl-tyrosine). The
limitations of the study are that we studied the effect
during only a relatively short period of amino acid
and/or protein supplementation and that we assessed
only whole-body protein turnover and not the specific
proteins or tissues.Conclusions
Supplemental parenteral amino acids can be used in
critically ill patients to stimulate whole-body protein
accretion during the initial week following ICU ad-
mission. The anabolic properties of such supplemental
amino acid administration can be effectively repeated
within merely a few days, still within the first week of
ICU treatment. Longer-term intervention studies are
Liebau et al. Critical Care  (2015) 19:106 Page 10 of 10needed to assess whether the anabolic properties of
supplemental amino acid provision can be sustained.
Key messages
 Supplemental parenteral amino acids can be used in
critically ill patients for body protein accretion
during the first week of ICU treatment.
 Extra parenteral amino acids given to critically ill
patients over the course of 3 hours are not oxidized.
 Whole-body protein turnover does not change in
critically ill patients during the initial week following
ICU admission.
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